Hutchison China MediTech: ASCO GU: promising PRCC data for savo/durva combo
Preliminary CALYPSO study presented at ASCO GU evidenced encouraging efficacy signals for the savolitinib and durvalumab combination in an all-comers papillary renal cell carcinoma (PRCC) population. CALYPSO is an exploratory single arm Phase I/II trial sponsored by Queen Mary University of London, which enrolled both treatment-naïve and previously treated PRCC patients. Hutchison China MediTech (Chi-Med) and partner AstraZeneca are currently reviewing their strategy for savolitinib development in kidney cancer; CALYPSO data will contribute to this, although more mature data is awaited. Chi-Med will present FY18 results and a pipeline update on March 11th. We value Chi-Med at £51.52/share or $33.49/ADS.Hutchison China MediTech is engaged in researching, developing, manufacturing and selling pharmaceuticals and healthcare products. Co. has research and development facilities and manufacturing plants in Shanghai and Guangzhou in the People's Republic of China and sells its products mainly in the PRC and Hong Kong. Co. operates two operating segments. The Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases, and the provision of research and development services. The Commercial Platform involves the manufacture, marketing and distribution of prescription and over the counter pharmaceuticals as well as consumer health products.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.